ArticleCureus2024
Patient and Tumor Factors on Overall Survival in Spindle Cell Melanoma.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionSpindle cell melanoma (SCM) is a rare melanoma subtype characterized histologically by atypical, spindled, malignant melanocytes. SCM often presents in older patients and lacks typical cytologic markers, complicating diagnosis and frequently leading to advanced disease upon presentation. While some studies have documented SCM incidence, none have thoroughly examined the demographic, socioeconomic, and treatment factors influencing survival outcomes.
objectiveThis study aims to investigate how demographic and clinical factors affect overall survival outcomes in SCM, providing updated data on demographic, socioeconomic, and tumor-related characteristics and treatment patterns.
methodsThis retrospective cohort study analyzed histologically confirmed spindle cell melanoma and mixed spindle cell melanoma cases diagnosed between 2004 and 2021. Patient demographic, socioeconomic, and clinical factors were collected, and multivariate Cox regression analysis was performed to determine the effects on overall survival.
resultsAmong 9,210 SCM cases, most were White patients (97.5%), male (65.2%), and located in metropolitan areas (85.7%). Males were more likely to receive treatment at academic centers and have higher comorbidity scores. The average age at diagnosis was 67.3 years (SD±15.1). SCM in head and neck regions showed a worse prognosis compared to extremity melanomas. Surgical intervention, received by 84.9% of patients, was associated with improved overall survival. The minority of patients who received radiation and chemotherapy (13.2% and 3.3%, respectively) were linked to increased mortality risk.
conclusionAge, sex, insurance status, treatment facility type, tumor location, and stage significantly influence SCM survival outcomes. The findings suggest that SCM's prognosis is closely tied to demographic and clinical characteristics, similar to other melanoma subtypes, supporting standard treatment protocols with surgical intervention as the primary approach. This large-scale study leverages comprehensive NCDB data, contributing to the literature gap in SCM's treatment and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.